-
InspireMD launches CGuard Prime carotid stent system in US market
-
InspireMD (NSPR) Announces FDA Approval for CGuard Prime Carotid Stent System for the Prevention of Stroke
-
InspireMD (NSPR) Announces CE Mark Approval for CGuard Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke
-
Piper Sandler Highlights Top Medtech Picks and Catalyst-Rich Names
-
InspireMD (NSPR) names Michael Lawless CFO
-
InspireMD (NSPR) PT Lowered to $4 but Piper Sandler Sees 'Opportunity for Significant Value Creation'
-
InspireMD (NSPR) Tops Q1 EPS by 9c
-
InspireMD (NSPR) Files $200M Mixed Shelf
-
InspireMD (NSPR) Tops Q4 EPS by 1c
-
InspireMD (NSPR) Announces CFO Change
-
InspireMD (NSPR)Appoints Scott R. Ward to its Board
-
InspireMD (NSPR) Tops Q3 EPS by 4c
-
InspireMD (NSPR) Announces Approval of IDE Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System
-
Piper Sandler Reiterates Overweight Rating on InspireMD (NSPR)
-
InspireMD (NSPR) Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System
-
InspireMD (NSPR) Misses Q2 EPS by 3c

